Medigene AG to report full year 2022 financial results on March 29, 2023
Martinsried/Munich, March 15, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2022 on Wednesday, March 29, 2023.
Following the release of the full year 2022 financial results on Medigene’s website, the company will host a conference call that same day at 3 p.m. CET (9 a.m. ET).
Full details for the conference call and webcast are as follows:
Following the call, an archived webcast will be accessible on the Investors & Media section of the Medigene website: https://www.medigene.com/investors-media/reports-presentations
--- end of press release ---
Sandya von der Weid
In case you no longer wish to receive any information about Medigene, please inform us by e-mail ([email protected]). We will then delete your address from our distribution list.